IO Biotech Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025. During the meeting, David Smith was elected as a Class I director. Additionally, the stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Both proposals were approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IO Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-137894), on June 09, 2025, and is solely responsible for the information contained therein.